Mesaflor (Mesalazine)

Mesalazine acts locally in the colon, inhibiting cyclooxygenase and lipoxygenase enzymes, which lowers prostaglandin and leukotriene production. It also scavenges free radicals, resulting in decreased mucosal inflammation and promotion of intestinal healing.

The specific dose of Mesaflor is determined by the prescribing clinician based on the patient’s disease severity, location, and response to therapy. Dosage adjustments are made according to individual clinical judgment.

Safety data for mesalazine in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and discuss any concerns with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mesaflor delivers mesalazine directly to the colon, similar to other 5‑ASA formulations. Differences may lie in release technology, dosing frequency, and patient tolerance. Clinicians choose based on efficacy, side‑effect profile, and convenience for the individual patient.

Mesaflor should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Mesaflor is taken orally, usually with water. The tablet should be swallowed whole unless the prescriber advises otherwise. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort.

Serious risks include pancreatitis, severe allergic reactions such as Stevens‑Johnson syndrome, blood dyscrasias (e.g., neutropenia), liver injury, and rare cardiac inflammation. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, rash, fever, or unexplained bruising.

Mesaflor is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored, and in those with a history of severe allergic reactions to 5‑ASA drugs.